397 related articles for article (PubMed ID: 37269391)
1. Application of Nano-Delivery Systems in Lymph Nodes for Tumor Immunotherapy.
Xia Y; Fu S; Ma Q; Liu Y; Zhang N
Nanomicro Lett; 2023 Jun; 15(1):145. PubMed ID: 37269391
[TBL] [Abstract][Full Text] [Related]
2. Lymph node-targeting nanovaccines for cancer immunotherapy.
Wang Q; Wang Z; Sun X; Jiang Q; Sun B; He Z; Zhang S; Luo C; Sun J
J Control Release; 2022 Nov; 351():102-122. PubMed ID: 36115556
[TBL] [Abstract][Full Text] [Related]
3. Recent Advances of Emerging Spleen-Targeting Nanovaccines for Immunotherapy.
He X; Wang J; Tang Y; Chiang ST; Han T; Chen Q; Qian C; Shen X; Li R; Ai X
Adv Healthc Mater; 2023 Sep; 12(23):e2300351. PubMed ID: 37289567
[TBL] [Abstract][Full Text] [Related]
4. Cascade Cytosol Delivery of Dual-Sensitive Micelle-Tailored Vaccine for Enhancing Cancer Immunotherapy.
Jiang D; Mu W; Pang X; Liu Y; Zhang N; Song Y; Garg S
ACS Appl Mater Interfaces; 2018 Nov; 10(44):37797-37811. PubMed ID: 30360105
[TBL] [Abstract][Full Text] [Related]
5. Combining Nanomedicine and Immunotherapy.
Shi Y; Lammers T
Acc Chem Res; 2019 Jun; 52(6):1543-1554. PubMed ID: 31120725
[TBL] [Abstract][Full Text] [Related]
6. In Situ Tumor Vaccine for Lymph Nodes Delivery and Cancer Therapy Based on Small Size Nanoadjuvant.
Zhang H; Zhang Y; Hu H; Yang W; Xia X; Lei L; Lin R; Li J; Li Y; Gao H
Small; 2023 Aug; 19(33):e2301041. PubMed ID: 37078903
[TBL] [Abstract][Full Text] [Related]
7. Chemical Strategies to Enhance the Therapeutic Efficacy of Toll-like Receptor Agonist Based Cancer Immunotherapy.
Lee SN; Jin SM; Shin HS; Lim YT
Acc Chem Res; 2020 Oct; 53(10):2081-2093. PubMed ID: 32966047
[TBL] [Abstract][Full Text] [Related]
8. Nano-Immune-Engineering Approaches to Advance Cancer Immunotherapy: Lessons from Ultra-pH-Sensitive Nanoparticles.
Li S; Bennett ZT; Sumer BD; Gao J
Acc Chem Res; 2020 Nov; 53(11):2546-2557. PubMed ID: 33063517
[TBL] [Abstract][Full Text] [Related]
9. Blockade of immune checkpoints in lymph nodes through locoregional delivery augments cancer immunotherapy.
Francis DM; Manspeaker MP; Schudel A; Sestito LF; O'Melia MJ; Kissick HT; Pollack BP; Waller EK; Thomas SN
Sci Transl Med; 2020 Sep; 12(563):. PubMed ID: 32998971
[TBL] [Abstract][Full Text] [Related]
10. Tumor-draining lymph nodes are survival niches that support T cell priming against lymphatic transported tumor antigen and effects of immune checkpoint blockade in TNBC.
O'Melia MJ; Manspeaker MP; Thomas SN
Cancer Immunol Immunother; 2021 Aug; 70(8):2179-2195. PubMed ID: 33459842
[TBL] [Abstract][Full Text] [Related]
11. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
12. Nanotopography-based lymphatic delivery for improved anti-tumor responses to checkpoint blockade immunotherapy.
Kwon S; Velasquez FC; Rasmussen JC; Greives MR; Turner KD; Morrow JR; Hwu WJ; Ross RF; Zhang S; Sevick-Muraca EM
Theranostics; 2019; 9(26):8332-8343. PubMed ID: 31754400
[No Abstract] [Full Text] [Related]
13. Combination therapy of lymphatic drug delivery and total body irradiation in a metastatic lymph node and lung mouse model.
Sora S; Sukhbaatar A; Fukushige S; Mori S; Sakamoto M; Kodama T
Cancer Sci; 2023 Jan; 114(1):227-235. PubMed ID: 36056924
[TBL] [Abstract][Full Text] [Related]
14. Dynamic CD8
Rahim MK; Okholm TLH; Jones KB; McCarthy EE; Liu CC; Yee JL; Tamaki SJ; Marquez DM; Tenvooren I; Wai K; Cheung A; Davidson BR; Johri V; Samad B; O'Gorman WE; Krummel MF; van Zante A; Combes AJ; Angelo M; Fong L; Algazi AP; Ha P; Spitzer MH
Cell; 2023 Mar; 186(6):1127-1143.e18. PubMed ID: 36931243
[TBL] [Abstract][Full Text] [Related]
15. During early stages of cancer, neutrophils initiate anti-tumor immune responses in tumor-draining lymph nodes.
Pylaeva E; Korschunow G; Spyra I; Bordbari S; Siakaeva E; Ozel I; Domnich M; Squire A; Hasenberg A; Thangavelu K; Hussain T; Goetz M; Lang KS; Gunzer M; Hansen W; Buer J; Bankfalvi A; Lang S; Jablonska J
Cell Rep; 2022 Aug; 40(7):111171. PubMed ID: 35977505
[TBL] [Abstract][Full Text] [Related]
16. Personalized Cancer Immunotherapy via Transporting Endogenous Tumor Antigens to Lymph Nodes Mediated by Nano Fe
Wang B; An J; Zhang H; Zhang S; Zhang H; Wang L; Zhang H; Zhang Z
Small; 2018 Sep; 14(38):e1801372. PubMed ID: 30080304
[TBL] [Abstract][Full Text] [Related]
17. Nanovaccine-based strategies for lymph node targeted delivery and imaging in tumor immunotherapy.
He A; Li X; Dai Z; Li Q; Zhang Y; Ding M; Wen ZF; Mou Y; Dong H
J Nanobiotechnology; 2023 Jul; 21(1):236. PubMed ID: 37482608
[TBL] [Abstract][Full Text] [Related]
18. gammadelta T lymphocytes count is normal and expandable in peripheral blood of patients with follicular lymphoma, whereas it is decreased in tumor lymph nodes compared with inflammatory lymph nodes.
Braza MS; Caraux A; Rousset T; Lafaye de Micheaux S; Sicard H; Squiban P; Costes V; Klein B; Rossi JF
J Immunol; 2010 Jan; 184(1):134-40. PubMed ID: 19949101
[TBL] [Abstract][Full Text] [Related]
19. Lymph node-targeted immune-activation mediated by imiquimod-loaded mesoporous polydopamine based-nanocarriers.
Wang L; He Y; He T; Liu G; Lin C; Li K; Lu L; Cai K
Biomaterials; 2020 Oct; 255():120208. PubMed ID: 32569862
[TBL] [Abstract][Full Text] [Related]
20. Dawn of lipid nanoparticles in lymph node targeting: Potential in cancer immunotherapy.
Nakamura T; Harashima H
Adv Drug Deliv Rev; 2020 Dec; 167():78-88. PubMed ID: 32512027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
